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The aim of this paper is to provide an overview of the current scientific and economic thinking on the use of genetic technologies for
cystic fibrosis (CF) screening. The paper takes a public health genetics viewpoint and gives an overview of the genetics behind CF, then
describes current practices in screening for the disease. We then discuss the current literature on the economic evaluations of screening for
CF. As the “wet” science improves, there are direct implications for health service. Therefore, it is important to keep examining both clinical
practice and economics behind the technologies.
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The purpose of this paper is to provide an overview of the
current scientific and economic thinking on the use of genetic
technologies for cystic fibrosis (CF) screening. CF, a life-
threatening disease that progressively worsens over time, most
commonly occurs in people of Caucasian extraction. It causesed by Elsevier B.V. All rights reserved.
256 P. Brice et al. / Journal of Cystic Fibrosis 6 (2007) 255–261severe respiratory problems and inadequate pancreatic function
due to the production of excess sticky mucus; most males
affected by CF are also sterile. Disease severity varies between
affected individuals. Death usually results from respiratory
failure, although improvements in treatment in recent years
have increased average life expectancy to over 30 years. At
least half of individuals born with CF since 1990 are now
expected to live beyond 40, but there remains no known cure
for the disease.
The paper takes a public health genetics viewpoint and
will first give an overview of the genetics behind CF, then lay
out current practices in screening for the disease. The
remainder of the paper will be a discussion of the economic
evaluations carried out in the area of screening for CF.
2. Genetics and CF
Cystic fibrosis is caused by deleterious mutations in the
gene encoding the cystic fibrosis transmembrane conductance
regulator (CFTR), which regulates the transport of chloride
ions across epithelial cell membranes in the lungs, gut, pan-
creas and certain other organs. Inadequate or absent chloride
transport in individuals with CF leads to the accumulation of
mucus, which can cause blockages and makes infections more
likely. Excessive chloride output in the sweat increases the
probability of dehydration and mineral imbalances. These
features of the disease typically result in poor nutrition and
growth, frequent respiratory infections and lung damage,
although there are many other associated complications.
The CFTR gene on human chromosome 7 was identified in
1989.Cystic fibrosis is an autosomal recessive genetic disorder;
heterozygous carriers of CF mutations (about 4% of the
population) do not show symptoms of the disease. In order to be
affected, a child must inherit a CF mutation from both of its
parents. The chances of two carrier parents conceiving an
affected (homozygous) child are 1 in 4 for each pregnancy.
The prevalence of CF in populations of northern European
origin is around 1 in 2500 [1]. In the UK, a much lower
incidence of 1 in 12,000 births has been estimated for groups of
Asian origin, and this figure is likely to be lower still among
populations of Afro-Caribbean and Oriental origin [1]. In the
US, incidences among Asian-Americans, African-Americans
and Hispanics have been estimated at around one per 31,000,
15,000 and 9500 births, respectively [2]. Cystic fibrosis also
affects South American populations.
So far, well over 1000 different mutations have been
reported in the CFTR gene, but most are very rare. The most
common CF mutation is DF508 (also called Delta F508,
F508del orΔF508) a small deletion in the gene; this mutation
accounts for about 70–75% of CF cases in the UK, though
there is some regional variation. The frequency of different
mutations also varies in different ethnic groups; for example,
DF508 is present in fewer than half of Jewish, Afro-Caribbean
and Asian individuals with the disease, whereas the W1282X
mutation is present in around half of all Ashkenazi Jewish CF
carriers but is rare in other populations [1]. W1282X is alsocommon in Israel, most Mediterranean countries and north
Africa; overall, more than fifty mutations are common (with a
frequency in excess of 1%) in one or more European countries
or regions [3]. However, some mutations are so rare that they
are only known to exist in individual families.
The correlation between genotype and phenotype in cystic
fibrosis is variable, with a subgroup of patients experiencing
milder and later-onset symptoms and improved survival
rates. Certain mutations are associated with less severe forms
of the disease, notably less serious mutations that permit
partial function of the CFTR gene. However, genotype is a
poor predictor of lung function, which varies considerably
between patients sharing the same mutation (such as the
ΔF508 mutation). Environmental factors such as smoking or
malnutrition may also influence the severity of lung disease.
One report has proposed that a functional classification of
patients according to their CF genotype could be of value in
predicting likely clinical outcome, despite a substantial degree
of phenotypic variability among patients with similar or
identical mutations [4]. A commonly occurring CFTR genetic
variant present in around 1 in 10 of the general population has
been linked to a milder cystic fibrosis phenotype when present
in conjunction with a severe CFTR mutation; the length of an
adjacent region of TG repeats has been found to influence
disease severity and has been advanced as a potential
predictor of outcome [4–6]. There is also evidence to suggest
that other secondary genetic factors (besides the CFTR gene
itself) may influence the extent of lung disease in cystic
fibrosis patients. Candidate ‘modifier’ genes include inflam-
matory and anti-inflammatory mediators, molecules involved
in CFTR trafficking and mediators of airway reactivity.
3. Implications of current knowledge of the genetics of
cystic fibrosis
3.1. Genetic testing
Genetic testing for CF in the UK detectsΔF508 plus up to
20 other mutations, together accounting for 90% of CF
mutations in people of northern European origin, so that the
probability of detecting a mutation in both members of a
Caucasian CF-carrier couple is about 80%. In pregnancy, if a
couple are both known CF carriers, they can be offered
antenatal fetal genetic testing (via amniocentesis or chorionic
villus sampling, procedures with an associated miscarriage
risk of around 1%) to determine whether the fetus is affected.
This genetic test is virtually 100% accurate, although it
cannot predict the severity of disease. Alternative non-
invasive techniques for the analysis of fetal cells for cystic
fibrosis mutations are currently in development.
If a CF carrier is discovered in a family, cascade testing of
other family members can also be offered, generally to close
family members of child-bearing age, for whom the
information available may influence reproductive decisions,
although there may be ethical and economic issues associated
with this approach.
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Pilot programmes of various forms of population-
screening have been investigated; these include:
4.1. Antenatal and pre-conception carrier screening
Pregnant couples or those planning a pregnancy are
offered genetic testing for CF carrier status; if both parents
are found to be carriers they are offered antenatal genetic
testing. In couple screening, samples are taken from both
parents and the test is reported as positive only if both
parents are found to be carriers; the ethical issues associated
with non-disclosure of carrier status if only one parent is a
carrier are contentious. In sequential screening, a sample is
first taken from the woman and a sample from her partner is
requested only if the woman is found to be a carrier.
A nationwide programme of antenatal or pre-conceptional
carrier screening for CFmutations is available in theUS,where
a screening panel of 25 common mutations (recommended by
theAmericanCollege ofMedical Genetics) is routinely offered
to all couples who are Caucasian or have a family history of
CF, and is also available to couples of different lower risk
ethnic groups on request. Concerns have been raised about the
degree of compliance with guidelines to ensure that screening
should remain an informed and personal choice for parents.
There have been reports that in rare cases invasive testing and
even abortions may have been performed unnecessarily, due to
the misinterpretation of test results [7–9]. It has also been
suggested that screening is sometimes presented as a routine or
recommended procedure, rather than an optional choice.
There are plans for pilot schemes to precede a national
antenatal or pre-conceptional genetic screening programme to
be introduced in the UK. One publication [4] proposes that the
most appropriate form of prenatal screening is couple
screening, being safe, reliable and non-invasive and allowing
a 72% detection rate for a 0.1% false-positive rate, but the level
of priority for introducing this programme would depend on
cost-effectiveness which was not analysed by Wald and
colleagues. Another issue of potential concern in carrier
screening for CF is the situation of couples where one partner
is identified as a carrier; ten Kate [10] proposed that the risk for
a couple after testing for carrier status should not be greater
than before testing, but this would require a test sensitivity in
excess of 96%, which is not generally achievable.
4.2. Population-based screening
In practice there appears to be little demand for population
screening, as people only become interested in their carrier
status when considering having children.Widening uptake by
targeting specific groups such as school children would raise
problems of informed consent. There is also evidence that
information about carrier status and risk are not well retained
in the long term, and that some people who discover they are
carriers begin to have a poorer perception of their health.4.3. Neonatal screening
Neonatal screening for CF typically uses an initial
biochemical test for immunoreactive trypsin (IRT) in plasma,
followed by genetic testing in infants with raised IRT. If a CF
mutation is detected, a definitive diagnostic test for CF is
given, such as the sweat test for raised levels of secreted
chloride. The overall sensitivity of neonatal screening is about
85–90%. The introduction of DNA-based testing means that
unaffected heterozygous carriers of CF are detected, with a
consequent need for genetic counselling of the parents.
The rationale for neonatal screening is that very early
detection and treatment may improve outcomes for children
with CF; it may also be important to inform future reproductive
decision making by the parents. Whether early detection
actually does improve outcomes– particularly in countrieswith
good health care systems, where the majority of CF cases are
diagnosed in infancy – has been the subject of some debate.
Reviews of some early studies failed to find conclusive
evidence of benefit [1,11] butmore recent data have suggested a
possible decrease inmortality with screening [12–14] and there
is increasing evidence to support a link between screening and
improved nutritional status resulting in better growth and lower
morbidity [12,15]. Possible harms resulting from pre-symp-
tomatic diagnosis by neonatal screening include overly
aggressive treatment and earlier lung infection with Pseudo-
monas due to mixing with infected, older CF patients; these are
indirect harms linked to modifiable healthcare practices [16]. It
has been suggested that neonatal CF screening programmes
require very careful design in order to achieve a favourable
balance between the potential risks and benefits [17].
Psychosocial issues associated with neonatal screening
show a range of potential risks and benefits. Early identifica-
tion and diagnosis of children with CF spares parents the
anxiety typically experienced in the time between the onset of
symptoms and diagnosis (whichmay be a period of years), and
may also prevent a second affected pregnancy if parents
become aware of their carrier status before conceiving another
child. However, adverse psychosocial effects have been
reported for the families of children identified as carriers of
the CF mutation, a much larger group than those with the
disease. Farrell and Farrell [16] note that the key to ensuring
that neonatal screening achieves ‘more good than harm’ is
excellence in implementation, including effective communi-
cation of information and counselling for affected families.
Indeed, the provision of easily comprehensible information
and genetic counselling to interpret the true meaning of
positive results are essential components of all forms of genetic
testing and screening for CF.
In the UK, neonatal screening for CF in Northern
Ireland, Wales, and parts of England (East Anglia, Leeds,
Northampton, the West Midlands and the Trent region) has
been running since the nineteen eighties. It was introduced
throughout Scotland at the start of February 2003, and in 2004
it was announced that universal screeningwould be introduced
throughout England by April 2007. There have been reports
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258 P. Brice et al. / Journal of Cystic Fibrosis 6 (2007) 255–261that the CFTRmutation analysis used for neonatal genetic tests
in the UK should detect 96% of affected (homozygous) babies
[18] but the 1999 HTA review [1] suggests that a lower overall
detection rate of 86% is realistic, based on a population
prevalence of 1 in 2400. It has been questioned whether this
rate could be achieved for ethnic groups other than
Caucasians, where the prevalence of CF is lower. Australia
has a comprehensive neonatal screening programme for cystic
fibrosis, as does France, but provision in much of the rest of
Europe and in the US is patchy.
4.4. International genetic testing and screening for CF
The emergence of cystic fibrosis as a ‘pan-ethnic’ disease
poses new problems specifically associated with genetic
testing and screening, in addition to the scarcity of healthcare
resources in developing countries [19]. Even within
predominantly northern Caucasian populations such as that
of the UK, the efficacy of genetic testing for CF is reduced
among population subgroups of different ethnic origins due
to the different types and frequency of common CF
mutations in such groups. In other countries, this heteroge-
neity of common mutations between different subpopula-
tions can be even more marked, making the choice of the
most appropriate mutation panel for screening programmes
more difficult. Understanding of regional variations in CF
mutation frequencies to inform the creation of suitable
mutation panels is a prerequisite for delivery of high
sensitivity prenatal and neonatal screening programmes
and to avoid discrimination against population subgroups
[20]. One potential problem with the use of alternative
mutation panels for ethnic minority groups is that self-
reported ethnicity is not necessarily an accurate reflection of
genetic ancestry [21]. Another possibility would be the use
of much larger, pan-ethnic mutation panels that could detect
the presence of many more mutations [20] an option that may
be facilitated by current developments in array-based DNA
diagnostics.
5. Economic implications of screening for CF
It is often thought that screening for a disease is cost-
effective simply because it would mean that cases could be
either prevented and/or found earlier. However, this is not
always the case. The literature on CF does not necessarily
agree on the costs or benefits of screening (newborn or
otherwise). Detection of carriers and the number of
prevented affected foetuses are the main measures of benefits
in most economic evaluations of CF screening programmes.
The following is an overview of published literature found
when carrying out a critical review of economic evaluation and
genetics literature [22], as well as additional CF specific
searches using PubMed. There were limits on language
(English only) and time (1983–2006). All costs are reported in
2006 US dollars. However, it must be noted that the studies
used different methods of collecting and reporting cost data,
259P. Brice et al. / Journal of Cystic Fibrosis 6 (2007) 255–261therefore comparability is limited. A summary is listed in
Table 1.
Because of the variation between genotype and phenotype
in CF patients, and therefore different clinical pathways, it is
somewhat difficult to estimate the burden of illness on a local
(or national) economy. However, several studies [23–26] have
attempted to show the burden of the disease on their respective
centres. For example, Baumann et al. [23] found that from a
health insurance perspective in Germany, total annual
expenditure per CF patient amounted to €23,989 and that
costs rose with age and doubled in the first 18 years. They also
found that patients with chronic lung infection were more than
three times more expensive than those with no chronic lung
infection, illustrating that differing clinical pathways have
different associated costs of care. In the US, Lieu et al. [26]
found that the annual cost of medical care averaged $13,300
but ranged from $6200 for patients with mild disease to
$43,300 for patients with severe disease. When the authors
used observed costs (from the Cystic Fibrosis Foundation
computerised cost database) to extrapolate the costs for the
entire population of CF patients in the US, they estimated the
costs to be $314 million per year in 1996.
Screening for CF may help alleviate the burden of illness
(mostly by preventing affected foetuses and identifying
carriers). However, the evidence below shows a wide
variation in terms of costs and effectiveness. Almost all of
the studies found that the cost-effectiveness was strongly tied
to the couple's reproductive plans and the cost of the tests.
In the UK, Murray and colleagues [1] carried out a Health
Technology Assessment (HTA) of screening programmes for
CF. Within the review of the health economic literature they
found that a number of researchers [26–28], both in the UK
and US, have found that a combination of prenatal and
antenatal screening was the most cost-effective way to screen
for CF. Effectiveness of antenatal programmes in these
evaluations was usually measured as number of affected
pregnancies avoided (aborted), or number of carriers detected.
Rowley et al. [29] compared a prenatal screening
programme to not screening for CF. The authors found that
when prenatal screening is offered to 100,000 pregnant
women, the cost of screening per CF birth voluntarily averted
is $1,322,376 without a replacement child and $1,396,038
when there is a replacement child. When costs of direct and
indirect care are deducted from these figures (discounted at 3%
per annum), the costs fall to $294,078 and $367,740,
respectively. The authors also found that assuming a
replacement child is born, cost per QALY gained of offering
a test is $8290. The authors suggest that the cost per QALY
estimate seems to compare favourably with that of other
preventative measures carried out in the US. However, the
authors noted that the results were very sensitive to the cost of
the test, life expectancy of a CF child, and the probability of the
termination of an affected fetus.
More recently, van den Akker-van Marle et al. [30] used a
hypothetical cohort of pediatric cases in the Netherlands to
compare four different screening techniques. Using life yearsgained as an outcome measure, the authors found that IRT+
IRT had the most favourable cost-effectiveness ratio of
€24800 per life-year gained. However, the incremental costs
per life-year gained of the IRT+DNA+denaturing gradient
gel electrophoresis strategy compared with the biochemical
screening only strategy were €130700, whereas the
incremental costs of the IRT+DNA strategy compared
with the IRT+DNA+denaturing gradient gel electrophoresis
strategy were €2154300. The authors also looked at the
effects of screening on future reproductive decisions and
found that depending on which screening strategy was used,
the health system could save up to €1.8 million annually.
Asch and colleagues [31] carried out a cost-effectiveness
analysis that compared 15 different carrier screening strategies
to no screening. The authors used CF births avoided as an
outcome measure. They found the cost-effectiveness ratio
ranged from $367,000 to $930,000 per CF birth avoided
depending on which strategy was adopted (sequential carrier
screening and couple screening respectively) compared to no
screening. The authors found that the cost-effectiveness was
greatly dependent on the couples' reproductive plans.
Cuckle and colleagues [27] analysed two different
antenatal screening strategies for CF: sequential carrier
testing (mother, then partner) and couple carrier testing
(mother and partner). The outcome measure used for the
analysis was the number of affected pregnancies detected.
The authors found that the cost to the health care system of
sequential screening was estimated to be £46,000 per
affected pregnancy detected. The cost of couple screening
was estimated to be £53,000 per affected pregnancy
detected. The authors found that the screening programme's
cost-effectiveness was sensitive to the cost of the test and the
proportion of carriers it can detect.
The cost-effectiveness of screening programmes seems to
be very sensitive to changes in assumptions on the birth of
‘replacement’ children, costs of the DNA test and whether the
study takes into account screening past the initial fetus (for
subsequent pregnancies). These conclusions are also sup-
ported in Asch et al. [31]. However, in Denmark, Nielsen and
Gyrd-Hansen [32] carried out a cost-effectiveness analysis
which found that introducing a prenatal screening programme
could be net cost saving from both a societal and health service
perspective, whether or not a replacement child is born. In their
analysis, costs per CF patient ranged from€296,154 over their
lifetime, whereas estimated benefits for avoiding a case of CF
ranged from €282,692 to 592,307. Such cost-effectiveness
analyses do not take account of the intangible quality and value
and length of life questions for parents and health workers that
accompany decisions to opt for screening tests, and/or for
termination of pregnancy.
6. Discussion
Similar to other health areas, the CF literature uses various
health economics techniques to describe costs and benefits and
are therefore difficult to comparewith any accuracy. Doran and
260 P. Brice et al. / Journal of Cystic Fibrosis 6 (2007) 255–261Vos [33] discuss the use of cost-effectiveness analysis in CF
and mention that given the increasing pressure on resources, it
is important for studies to be carried out in a methodologically
comparable manner. The authors site two of the most
commonly used recommendations [34,35]. Both try to give
checklists and guidelines on how to prepare a quality economic
evaluation. Another excellent resource for preparing economic
evaluations is the National Health Service Economic Evalu-
ation Database (NHSEED) which can be found on the York
University Web site (http://www.york.ac.uk/inst/crd/index.
htm). Many studies used decision tree and other types of
modelling techniques were used by many of the authors. In
addition to the economic evaluation guidelines, authors may
also find the guidelines produced by the International Society
for Pharmacoeconomic and Outcomes Research (ISPOR)
helpful [36].Wewould also encourage future authors to use all
these guidelines before attempting to do an economic analysis.
It is often the casewith genetic technologies (not just within
CF) that outcome measures are difficult to quantify. It is
apparent in the literature that relatively simple outcome
measures of birth(s) avoided or case detected is common.
However, increasingly economists are using the QALY in
order to capture health outcomes and quality of life. However,
it can (and is) argued that neither of these measures is adequate
to value the outcome of a genetic test or screening programme.
Future authors may want to investigate techniques such as
willingness-to-pay and/or discrete choice experiments in order
to incorporate both health and non-health benefits of a genetic
screening programme (see [37–39] for a description of these
techniques). There is disagreement among economists over
what the “best” outcome measure is for economic evaluations
of screening programmes. As Doran and Vos [33] point out,
“the perspective adopted for an economic evaluation needs to
reflect the purpose of the research.” The same is true for the
outcome measures as well as costs.
Work in the area of CF screening is progressing. The more
information gathered from the human genome on the
interactions of genes and environment will no doubt add
much to the techniques used to screen for CF and the treatment
paths for patients suffering from the disease. It is important to
note that while we are constantly making advances in the ‘wet’
science, the ability to implement them in a health setting may
be limited. It is therefore important to keep examining both
clinical practice and the economics behind the technologies.
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